4/3
12:11 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $5.00 price target on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $5.00 price target on the stock.
3/28
11:03 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/27
08:33 am
apto
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
08:08 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
3/26
04:18 pm
apto
Aptose Reports Results for the Fourth Quarter and Full Year 2023 [Yahoo! Finance]
Medium
Report
Aptose Reports Results for the Fourth Quarter and Full Year 2023 [Yahoo! Finance]
3/26
04:10 pm
apto
Aptose Reports Results for the Fourth Quarter and Full Year 2023 [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Aptose Reports Results for the Fourth Quarter and Full Year 2023 [Financial Post (Toronto, Ontario, Canada)]
3/26
04:01 pm
apto
Aptose Reports Results for the Fourth Quarter and Full Year 2023
Medium
Report
Aptose Reports Results for the Fourth Quarter and Full Year 2023
3/18
11:06 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Neutral
Report
Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/18
04:30 pm
apto
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
Low
Report
Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
2/1
03:30 pm
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at Piper Sandler from $12.00 to $5.00. They now have an "overweight" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its price target lowered by analysts at Piper Sandler from $12.00 to $5.00. They now have an "overweight" rating on the stock.
1/31
10:58 pm
apto
HANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC. [Yahoo! Finance]
Low
Report
HANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC. [Yahoo! Finance]
1/31
04:21 pm
apto
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option [Yahoo! Finance]
Low
Report
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option [Yahoo! Finance]
1/31
04:08 pm
apto
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option [Financial Post (Toronto, Ontario, Canada)]
1/31
04:01 pm
apto
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
Low
Report
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
1/29
08:49 am
apto
This Aptose Biosciences Insider Increased Their Holding In The Last Year [Yahoo! Finance]
Low
Report
This Aptose Biosciences Insider Increased Their Holding In The Last Year [Yahoo! Finance]